[Experience in treating metabolic osteopathies with 1 alpha-hydroxyvitamin D3 (oksidevit)].
The action of 1 alpha-hydroxycholecalciferol (oxydevit) was estimated in 204 patients with renal osteodystrophy, osteoporosis of varying etiology, osteomalacia because of malabsorption, congenital rickets-like diseases. The drug was shown to be highly effective in the treatment of secondary hyperparathyroidism in uremia, steroidal and senile osteoporosis. The treatment involved replacement therapy.
Babarykin
D A
DA
Reĭsner
N A
NA
Riabukha
A N
AN
Rozental'
R L
RL
D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000378:metabolism; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D010018:Osteomalacia / Q000188:drug therapy / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy / Q000378:metabolism; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000378:metabolism; D012279:Rickets / Q000151:congenital / Q000188:drug therapy / Q000378:metabolism
D006887:Hydroxycholecalciferols; C008088:alfacalcidol
Opyt lecheniia metabolicheskikh osteopatiĭ 1 al'fa-gidroksivitaminom D3 (oksidevitom).